Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01578187 · ClinicalTrials.gov registry record · NA
Hair2Go Label Comprehension and Usability Study
A NA study, sponsored by Syneron Medical.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT01578187: Completed NA study, sponsored by Syneron Medical.
NCT01578187 is a NA study that has completed, run by Syneron Medical. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01578187, a NA study, has completed, sponsored by Syneron Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to test label comprehension and usability of the hair removal device in 60 male and female participants. The study population will represent the US demographic distribution of skin types and will include varying levels of literacy.
Primary Outcome
Label comprehension will be based on responses to a questionnaire. Questions will be based on a tiered system by level of importance in responding correctly according to the following: 1. Questions regarding safe use of the system. 2. Questions regarding correct use of the system(not related to safety). In order to demonstrate how well the label instruction, as a whole, was understood by all subjects, the proportion of subjects who correctly understood the label as a whole was calculated by cl
Interventions
- DEVICE Hair2Go
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-06 |
| Phase | NA |
What the finished NCT01578187 record still lists
NCT01578187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Hair2Go is the first listed.
NCT01578187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01578187 about?
NCT01578187 is a clinical study titled "Hair2Go Label Comprehension and Usability Study". The purpose of this study is to test label comprehension and usability of the hair removal device in 60 male and female participants. The study population will represent the US demographic distribution of skin types and will include varying levels of literacy.
What is the current status of trial NCT01578187?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2012-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01578187?
The interventions under investigation include: Hair2Go (DEVICE).
Who is sponsoring clinical trial NCT01578187?
This trial is sponsored by Syneron Medical, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01578187's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia